Luye pharma group ltd. private company information – bloomberg lower chest pain

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products. The company offers Maitongna for cerebral edema and edema caused by trauma; Xuezhikang, a blood lipid regulator capsule; Tiandida for ovarian or non-small cell lung cancer; Yitaida for acute promyelocytic leukemia and liver cancer; CMNa for tumor radiotherapy; LIPUSU for ovarian, metastatic ovarian, breast, and non-small-cell lung cancer patient; Nuosen for acute upper digestive tract hemorrhage; Bei Tang Ning, a capsule to control blood glucose in patients with type 2 diabetes; Bei Xi, an acarbose capsule for diabetes; and LUTINGNUO, reduced glutathione injection for toxici…

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products.


The company offers Maitongna for cerebral edema and edema caused by trauma; Xuezhikang, a blood lipid regulator capsule; Tiandida for ovarian or non-small cell lung cancer; Yitaida for acute promyelocytic leukemia and liver cancer; CMNa for tumor radiotherapy; LIPUSU for ovarian, metastatic ovarian, breast, and non-small-cell lung cancer patient; Nuosen for acute upper digestive tract hemorrhage; Bei Tang Ning, a capsule to control blood glucose in patients with type 2 diabetes; Bei Xi, an acarbose capsule for diabetes; and LUTINGNUO, reduced glutathione injection for toxicity, and injuries caused by ionizing radiation, as well as for hypoxemia. It also provides Glucosamine Hydrochloride tablets for osteoarthritis; Xi Ming Ting largetrifoliolious bugbane rhizome total saponin tablets for invigorating splenic yang and relieving depression, and treating perimenopausal syndrome in females, as well as improving the symptoms of hot flashes, sweating, irritability, insomnia, hypochondriac pain, dizziness and tinnitus, aching pain of waist and knee, melancholy, unhappy, etc. In addition, the company provides Oukai sodium aescinate tablets for soft tissue swelling and venous edema; Oulai, a compound sodium aescinate gel for local swelling induced by inflammation, degenerative lesion, and trauma; Sidinuo for osteoporosis and relieving pain induced by osteoporosis; Outong, a capsaicin gel; and Jinsiping selegiline hydrochloride tablets for Parkinson’s disease. Further, it distributes, sells, and retails pharmaceutical drugs; manufactures and sells eggs; and provides business and investment consultation, as well as contract research, process development, and manufacturing services. The company has strategic collaboration with Excel BioPharm LLC. The company was founded in 1994 and is headquartered in Yantai, the People’s Republic of China.

AstraZeneca has entered into an agreement with Luye Pharma Group Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa. The transaction is part of AstraZeneca’s strategy to focus on its three main therapy areas of Oncology, Cardiovascular, Renal Metabolism and Respiratory. Seroquel, used primarily to treat schizophrenia and bipolar disease, has lost its compound patent protection globally; the Seroquel XR formulation patents have now also expired in the vast majority of markets. AstraZeneca partnered the rights to Seroquel and Seroquel XR in Japan and Venezuela under prior agreements. Financial considerations Luye Pharma will pay $538 million in consideration including $260 million immediately following closure of the transaction. In addition, a milestone is payable on the successful transition of certain activities to Luye. AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Luye Pharma during a transition period. The upfront and future payments will be reported as Other Operating Income in the Company’s financial statements. The transaction is expected to close by the end of second quarter of 2018, subject to customary closing conditions and regulatory clearances. In the fiscal year 2017, Seroquel generated annual sales of $85 million in the markets covered by this agreement, while Seroquel XR generated $63 million. The agreement does not change the Company’s financial guidance for the fiscal year 2018.